Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | MB | P02144 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879793 | 0.85 | PKM (0.59) | PKMALDH1A1MAPTCA12CA1 | |
| SCHEMBL7659979 | 0.84 | HTT (0.54) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL3192352 | 0.82 | PKM (0.65) | PKMALDH1A1MAPTCA12CA1 | |
| SCHEMBL8032430 | 0.81 | MEN1 (0.50) | PKMALDH1A1MAPTCA12CA1 | |
| SCHEMBL11638580 | 0.81 | CA1 (0.60) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL2556808 | 0.81 | SMN1; SMN2 (0.57) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL31094956 | 0.81 | SMN1; SMN2 (0.57) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL16504459 | 0.80 | KDM5A (0.59) | PKMALDH1A1MAPTCA12CA1 | |
| SCHEMBL23885336 | 0.79 | HDAC1 (0.54) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL147440 | 0.79 | IDO1 (0.65) | ALDH1A1MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0704539-B1 | Chemiluminescent reagent and assay using a substituted acetanilide for light generation | JOHNSON & JOHNSON CLIN DIAG (US) | 2001-02-28 | — | — | EP | claimed |
| US-5705357-A | DETECTING PEROXIDASE; SENSITIVITY, LOW BACKGROUND; MEDICAL DIAGNOSIS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1998-01-06 | — | — | US | claimed |
| EP-0704539-A2 | Chemiluminescent reagent and assay using a substituted acetanilide for light generation | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-03 | — | — | EP | claimed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| US-5705357-A | DETECTING PEROXIDASE; SENSITIVITY, LOW BACKGROUND; MEDICAL DIAGNOSIS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5641635-A | Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents | EASTMAN KODAK COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0704539-A2 | Chemiluminescent reagent and assay using a substituted acetanilide for light generation | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5372931-A | Use of 4'-hydroxy- and 4'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods | EASTMAN KODAK COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5372932-A | Peroxidase-labeled immunoreactant; stabiliztion with a 4-hydroxy or 4-alkoxyarylacetamide | EASTMAN KODAK COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0603953-A1 | Use of 4' of 5'-hydroxy and 4'- or 5'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0603954-A2 | Analytical element and immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | PKM 1294/4885ALDH1A1 299/4885MAPT 3178/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | PKM 4011/4885ALDH1A1 623/4885MAPT 4782/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | PKM 4011/4885ALDH1A1 623/4885MAPT 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.